Download
1 / 14
140 likes | 157 Views
The increasing utilization of antibiotics, which leads to the loss of beneficial bacteria that keep the vaginal ecosystem balanced, is primarily driving the vulvovaginal candidiasis market.
E N D
ABOUT IMARC International Market Analysis Research and Consulting Group is a leading adviser on management strategy and market research worldwide. We partner with clients in all regions and industry verticals to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise. IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.
Report Description and Highlights Vulvovaginal Candidiasis Market 2023-2033 IMARC Group has recently released a report titled “Vulvovaginal Candidiasis Market: Analysis of Epidemiology, Industry Trends, Size, Share, and Future Forecast (2023-2033)” that presents a comprehensive assessment of the vulvovaginal candidiasis market. The report provides an extensive overview of the latest market trends, growth prospects, investment opportunities, and industry outlook, as well as an in-depth analysis of the disease landscape, market size, and growth trends. Furthermore, the report offers an analysis of competitors, regional markets, and recent advancements in the global market. It also sheds light on crucial segments and market drivers, along with challenges faced by industry players. This report is a valuable resource for stakeholders who want to gain valuable insights into the vulvovaginal candidiasis market. Vulvovaginal candidiasis, also known as vaginal yeast infection, is a fungal infection that occurs due to an infestation of the fungus Candida in the vulva and vagina. The most common indications associated with the disease include itching, a burning sensation while peeing, soreness in the vaginal area, and thick, white, odorless discharge. An individual suffering from vulvovaginal candidiasis may also experience pain during sex and general discomfort in the genital region. The diagnosis of this ailment involves a physical examination by a healthcare provider, such as a pelvic exam and a swab test of the vaginal discharge.
Report Description and Highlights Vulvovaginal Candidiasis Market Trend: The increasing utilization of antibiotics, which leads to the loss of beneficial bacteria that keep the vaginal ecosystem balanced, is primarily driving the vulvovaginal candidiasis market. Additionally, the growing prevalence of various associated risk factors, such as hormonal changes, weakened immune systems, poor personal hygiene, sexual relations with multiple partners, etc., is further catalyzing the market growth. Besides this, the rising utilization of over-the-counter antifungal creams containing active ingredients, including miconazole, clotrimazole, tioconazole, etc., to treat mild to moderate symptoms of the condition is acting as another significant growth-inducing factor. Furthermore, the escalating adoption of probiotics as supplements to restore the natural balance of bacteria in the vaginal region is creating a positive outlook for the market. Additionally, the ongoing advancements in molecular diagnostic methods that can identify Candida species with high sensitivity and specificity are also contributing to the market growth. Apart from this, the emerging popularity of non-pharmacological therapies, such as stress-reduction techniques and dietary changes like minimizing sugar intake to manage disease symptoms, is anticipated to propel the vulvovaginal candidiasis market in the coming years. Request a Sample Report: https://www.imarcgroup.com/vulvovaginal-candidiasis-market/requestsample
Report Description and Highlights What is included in the report segmentation? The report covers the following aspects: Report Period: • Base Year: 2022 • Historical Period: 2017-2022 • Market Forecast: 2023-2033 Countries Included: • United States • Germany • France
Report Description and Highlights • United Kingdom • Italy • Spain • Japan Analysis Covered Across Each Country • Historical, current, and future epidemiology scenario • Historical, current, and future performance of the Vulvovaginal Candidiasis market • Historical, current, and future performance of various therapeutic categories in the market • Sales of various drugs across the Vulvovaginal Candidiasis market • Reimbursement scenario in the market • In-market and pipeline drugs
Report Description and Highlights In-Market Drugs • Drug Overview • Mechanism of Action • Regulatory Status • Clinical Trial Results • Drug Uptake and Market Performance Late-Stage Pipeline Drugs • Drug Overview • Mechanism of Action • Regulatory Status • Clinical Trial Results • Regulatory Status View Report TOC, Figures and Tables: https://www.imarcgroup.com/vulvovaginal-candidiasis-market
Key Questions Answered in the Report • How has the Vulvovaginal Candidiasis Market performed so far and how will it perform in the coming years? • What are the markets shares of various therapeutic segments in 2022 and how are they expected to perform till 2033? • What was the country-wise size of the Vulvovaginal Candidiasis Market across the seven major markets in 2022 and what will it look like in 2033? • What is the growth rate of the Vulvovaginal Candidiasis Marketacross the seven major markets and what will be the expected growth over the next ten years? • What are the key unmet needs in the market?
Table of Contents 1 Preface 2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary
Table of Contents 4 Vulvovaginal Candidiasis - Introduction 4.1 Overview 4.2 Regulatory Process 4.3 Epidemiology (2017-2022) and Forecast (2023-2033) 4.4 Market Overview (2017-2022) and Forecast (2023-2033) 4.5 Competitive Intelligence 5 Vulvovaginal Candidiasis - Disease Overview 5.1 Introduction 5.2 Symptoms and Diagnosis 5.3 Pathophysiology 5.4 Causes and Risk Factors 5.5 Treatment Click here to visit the complete table of content with list of figures and tables: https://www.imarcgroup.com/vulvovaginal-candidiasis-market/toc
Disclaimer © 2023 IMARC All Rights Reserved This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC). Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication. IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.
